THE ROLE OF ENDOCRINE FACTORS AND HEAT SHOCK PROTEINS (HSP60 AND GROEL) IN PREDICTING THE EFFECTIVENESS OF TREATMENT OF CLIMACTERIC SYNDROME

Authors:

Abstract:

The research was carried out during the examination and treatment of 158 patients with the climacteric syndrome. The patients were divided into two groups: 1 group included 80 patients receiving menopausal hormone therapy; group 2 included 78 women who were not treated. All patients from two groups had their levels determined: anti-Müllerian hormone, follicle-stimulating hormone, luteinising hormone, and thyroid-stimulating hormone. In addition, a study of the level of antibodies (IgG) to human heat shock protein 60 (HSP60) and its bacterial homolog (GroEl) was conducted. As a result of the multivariate analysis, a reduction (p=0.012) of the risk of not achieving the effect of treatment due to symptoms of estrogen-deficiency state was found for treated patients, OR=0.29 (95 % CI 0.11–0.76) in comparison with the untreated group female patients (when standardised by the level of anti-Müllerian hormone). A higher (p=0.017) risk of not achieving the effect of treatment due to symptoms of an estrogen-deficient state revealed at a higher level of anti-Müllerian hormone, OR=6.1 (95 % CI 1.4–27) for every 1 ng/ml. Indicators of HSP60 and GroEl do not affect the effectiveness of treatment of clinical manifestations of estrogen deficiency.

Keywords:

perimenopause climacteric syndrome menopausal hormone therapy HSP60

References:

1. Abrahami N, Izhaki I, Younis JS. Is there a difference in ovarian reserve biomarkers and ovarian response between the right and left ovaries? Reproductive BioMedicine Online. 2020;41(3):416–424. DOI: 10.1016/j.rbmo.2020.06.007.
2. Berestoviy V, Mahmood A, Venckivska I, Ginzburg V, Sokol I, Berestoviy O, et al. The overview and role of heat shock proteins (HSP) especially HSP 60 and 70 in reproduction and other pathologies (a literature review). Medychni perspektyvy. 2021;26(1):54–62. DOI: 10.26641/2307-0404.2021.1.227733.
3. De Villiers T, Hall J, Pinkerton J, Pérez SC, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016;91:153–155. DOI: 10.1016/j.maturitas.2016.06.001.
4. Dillon KE, Gracia CR. What is normal ovarian reserve? Seminars in reproductive medicine. 2013;31(06):427–436. DOI: 10.1055/s-0033-1356478.
5. Fait T. Menopause hormone therapy: latest developments and clinical practice. Drugs in context. 2019;8. DOI: 10.7573/dic.212551.
6. Freeman EW, Sammel MD, Lin H, Boorman DW, Gracia CR. Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women. Fertility and sterility. 2012;98(5):1254–1259. DOI: 10.1016/j.fertnstert.2012.07.1139.
7. Gold EB. The timing of the age at which natural menopause occurs. Obstetrics and Gynecology Clinics. 2011;38(3):425–440. DOI: 10.1016/j.ogc.2011.05.002.
8. Kim C, Slaughter JC, Wang ET, Appiah D, Schreiner P, Leader B, et al. Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas. 2017;102:18–25. DOI: 10.1016/j.maturitas.2017.04.018.
9. Kruszyńska A, Słowińska-Srzednicka J. Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Menopause Review/Przegląd Menopauzalny. 2017;16(2):47–50. DOI: 10.5114/pm.2017.68591.
10. Landstein D, Ulmansky R, Naparstek Y. HSP60–a double edge sword in autoimmunity. Oncotarget. 2015;6(32):32299.
11. Moolhuijsen LM, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. The Journal of Clinical Endocrinology & Metabolism. 2020;105(11):3361–3373. DOI: 10.1210/clinem/dgaa513.
12. Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, Wyroba J, Tomczyk R, Wiatr J, et al. Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women. Menopause Review/Przegląd Menopauzalny. 2015;14(4):218–222. DOI: 5114/pm.2015.56402.
13. Santoro N. Using Antimüllerian hormone to predict fertility. Jama. 2017;318(14):1333–1334. DOI: 10.1001/jama.2017.14954.
14. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The North American Menopause Society, New York. 2017;24(7):728–753. DOI: 10.1097/GME.0000000000000921

Publication:

«World of Medicine and Biology» Vol. 18 No. 81 (2022) , с. 178-182
УДК 618.173-085.357:612.43:577.112

DOI:

https://doi.org/10.26724/2079-8334-2022-3-81-178-182